Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin for Acute Bacterial Sinusitis
NCT00492024Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2005
- Primary completion
- Mar 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute bacterial sinusitis (ABS) comparing Moxifloxacin 400 mg with Placebo (2 arms). Primary endpoint: Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT)). Started Jan 2005; status: completed.
02
Drugs
moxifloxacin
03
Conditions
acute bacterial sinusitis (ABS)
Beyond the preview
Go deeper on NCT00492024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492024.